Cyclobenzaprine: Nursing Drug Guide, Serotonin Syndrome & NCLEX Review
Healthcare medication guide: screen every order for MAOI use within 14 days and serotonergic combinations (SSRIs, SNRIs, TCAs, tramadol, bupropion)—then pair sedation and fall precautions with short-term spasm therapy capped at 30 mg/day.
Do not give cyclobenzaprine with MAO inhibitors or within 14 days of MAOI use. U.S. labeling warns of serotonin syndrome when cyclobenzaprine is combined with serotonergic drugs—including SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, and MAOIs. Early signs may include agitation, hallucinations, hyperthermia, tachycardia, labile blood pressure, hyperreflexia, tremor, diaphoresis, and GI symptoms. Hold the drug, review the full medication list, and escalate per facility protocol. Secondary risks include marked sedation, dizziness, and falls, especially with alcohol and other CNS depressants.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before the first cyclobenzaprine dose, confirm no MAOI within 14 days and reconcile all serotonergic medicines—a common miss is home SSRI or tramadol therapy plus a new spasm order. If agitation, hyperreflexia, or fever appear after dosing, treat as possible serotonin toxicity until ruled out.
Most common brand names
Immediate-release (IR) and extended-release (ER) oral products are available. Do not interchange IR milligram-for-milligram with ER without prescriber and pharmacy conversion.
Common U.S. brand names include Flexeril (IR), Fexmid (IR), and Amrix (ER). Generic cyclobenzaprine is widely used for short-term musculoskeletal spasm.
Why we give it — Indications
Per current U.S. prescribing information, cyclobenzaprine is indicated as an adjunct to rest and physical therapy for relief of acute, painful musculoskeletal muscle spasm. It is for short-term use only (2–3 weeks) because muscle spasm associated with acute, painful musculoskeletal conditions is generally short-lived.
It is not effective in spasticity from cerebral or spinal cord disease, or in children with cerebral palsy. Do not use for chronic spasticity management—that pathway belongs to neurologic spasticity agents (for example baclofen) rather than short-term cyclobenzaprine orders.
| Use | Detail |
|---|---|
| Acute musculoskeletal spasm | Adjunct to rest and PT for painful muscle spasms (e.g. back pain, neck pain) |
| Duration | Limit to 2–3 weeks; reassess if spasm persists |
| Not indicated | Spasticity from cerebral/spinal cord disease; cerebral palsy spasticity in children |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants. Its action on acute musculoskeletal spasm is thought to occur primarily in the central nervous system at brain stem level rather than at the neuromuscular junction or muscle fiber. Atropine-like (anticholinergic) effects contribute to dry mouth, urinary retention risk, and caution with other anticholinergics.
Dosing overview
Immediate-release dosing starts low and may be titrated for effect within the labeled maximum. Elderly and hepatically impaired patients need slower titration and less frequent dosing.
| Scenario | Dose adjustment (labeling) |
|---|---|
| Mild hepatic impairment | Start 5 mg and titrate cautiously |
| Moderate–severe hepatic impairment | Not recommended |
| Pediatrics < 15 years | Safety and effectiveness not established |
| Renal impairment | Use caution; no specific adjustment in labeling reviewed—monitor sedation |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: If a dose is missed, follow prescriber or pharmacy instructions—do not double doses. Repeated extra doses increase sedation and overdose risk.
Before you give it — Safety check
Pretreatment checks
- Complete medication reconciliation for SSRIs, SNRIs, TCAs, tramadol, bupropion, MAOIs, and other serotonergic agents
- Confirm no MAO inhibitor use within 14 days
- Screen cardiac history: recent MI, arrhythmias, heart block, conduction disturbances, or heart failure—contraindicated per labeling
- Review hepatic function (ALT and clinical status)—avoid in moderate–severe impairment
- Assess anticholinergic risk: urinary retention, angle-closure glaucoma, concurrent anticholinergics
- Plan sedation and fall risk precautions, especially in older adults
Contraindications
- Hypersensitivity to cyclobenzaprine
- MAO inhibitors or use within 14 days of MAOI discontinuation
- Acute recovery phase of myocardial infarction
- Arrhythmias, heart block, conduction disturbances, congestive heart failure
- Hyperthyroidism
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| SSRIs / SNRIs (e.g., sertraline, fluoxetine) | Serotonin syndrome risk per boxed warning context in labeling | Hold cyclobenzaprine; notify prescriber/pharmacist; monitor temperature, reflexes, mental status |
| TCAs (e.g., amitriptyline) | Additive serotonergic and anticholinergic effects | Avoid combination unless specialist plan; watch for agitation and hyperreflexia |
| Tramadol, bupropion | Serotonin syndrome risk listed in labeling | Reconcile on admission; do not start cyclobenzaprine until interaction cleared |
| Alcohol, barbiturates, CNS depressants (e.g., diazepam, morphine) | Enhanced sedation and psychomotor impairment | Fall precautions; monitor RR and arousal; teach avoidance of alcohol |
| NSAIDs (e.g., ibuprofen) | Often co-prescribed for spasm—no direct serotonergic interaction but document combined sedation plan | Coordinate pain assessment and non-drug measures |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral route: Give IR tablets in divided doses per order. ER products (Amrix) have separate once-daily dosing—verify formulation on every pass.
- Confirm IR versus ER product and total daily dose ≤ 30 mg for IR unless prescriber documents otherwise
- May take with or without food; sedation may guide timing away from driving or PT
- Do not crush or split ER capsules unless product labeling and pharmacy approve
- Chart formulation changes on handoff—IR/ER errors are high-risk
Expected therapeutic response
- Reduced severity of acute painful musculoskeletal spasm within days when combined with rest and therapy
- Improved participation in prescribed movement and PT when pain and guarding decrease
- Mild drowsiness may occur early—excessive sedation, confusion, or autonomic symptoms suggest toxicity or interaction
Red flags — Stop and act
Escalate immediately for suspected serotonin syndrome, serious sedation or overdose, or cardiac toxicity.
- Serotonin syndrome: agitation, hallucinations, hyperthermia, tachycardia, labile BP, hyperreflexia, tremor, diaphoresis, incoordination—especially with SSRI/SNRI/TCA/tramadol/bupropion or MAOI exposure; hold cyclobenzaprine and notify prescriber immediately
- Overdose: marked somnolence, tachycardia, seizures, QRS widening, cardiac arrest—support airway, obtain ECG, contact poison control/toxicology per facility protocol
- New confusion, syncope, or inability to arouse after dose
- Urinary retention, severe abdominal distension, or acute angle-closure symptoms in at-risk patients
- Chest pain, palpitations, or syncope in patients with cardiac disease
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Drowsiness | 29–38% in labeling | Fall precautions; avoid driving; monitor with CNS depressants |
| Dry mouth | 21–32% | Oral care; hydration; assess swallowing |
| Dizziness, fatigue, headache | Common | Orthostatic checks; assist with transfers |
| Constipation | Anticholinergic-related | Bowel regimen; mobility; review other anticholinergics |
| Serotonin syndrome | Interaction-related—not a simple percentage AE | Hold drug; cooling and escalation per protocol; document all serotonergic agents |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Prescribing information does not list a specific antidote for cyclobenzaprine overdose. Early toxicity may include drowsiness and tachycardia; severe cases may involve cardiac arrest, seizures, and QRS widening.
Management (labeling)
- Gastric decontamination when appropriate
- ECG monitoring
- Supportive care
- Sodium bicarbonate for dysrhythmias per label and toxicology guidance
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for suspected overdose—especially with QRS widening, seizures, or respiratory depression.
Look-alike / sound-alike and error prevention
- Cyclobenzaprine vs cyclophosphamide, cyproheptadine—read back full generic name
- Flexeril IR vs Amrix ER—verify formulation; do not substitute ER for TID IR without conversion
- 10 mg TID versus 10 mg daily—independent double-check total daily dose ≤ 30 mg IR
- Home SSRI not on MAR—admission reconciliation gap is a common serotonin syndrome trigger
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Serotonin screen | Ask about antidepressants, tramadol, cough products, and recent MAOI use—even if “not taking anything new” |
| Short course | Flag orders beyond 2–3 weeks for prescriber review; spasm should improve with rest and PT |
| Sedation ladder | Expect drowsiness; schedule PT when most alert; avoid stacking with benzodiazepines and opioids when possible |
| Hepatic trend | Track ALT and clinical jaundice—hold in moderate–severe impairment |
| Commonly missed | Continuing cyclobenzaprine after SSRI starts; giving dose after patient took extra tablet at home |
| Ask pharmacy when | IR/ER conversion, hepatic dosing, or multi-drug serotonergic risk |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Greater sedation, anticholinergic effects, and fall risk—start 5 mg, titrate slowly, less frequent dosing |
| Hepatic impairment | Mild: start 5 mg and titrate; moderate–severe: not recommended |
| Cardiac disease | Contraindicated in recent MI, arrhythmias, heart block, CHF, hyperthyroidism |
| Patients on serotonergic therapy | High risk for serotonin syndrome—avoid combination or use only with explicit specialist plan |
| Pregnancy | Category B in animals; no adequate human studies—use only if benefit justifies risk |
| Lactation | Excretion in milk not known; TCA-related caution—consult LactMed and care team |
| Pediatrics < 15 years | Not established in labeling reviewed for this guide |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Spasm severity and functional response to rest, PT, and analgesics
- Sedation, orthostatic symptoms, and fall incidents
- Mental status, temperature, reflexes, and autonomic signs when serotonergic co-therapy exists
- Heart rate and rhythm in patients with cardiac history
- Hepatic symptoms and ALT trend when hepatic risk present
- Urinary output if anticholinergic burden is high
Document
- Formulation (IR vs ER), dose, route, time, and running daily total
- MAOI and serotonergic medication review completed before first dose
- Hold events, duplicate-dose concerns, and prescriber/pharmacy notifications
- Patient teaching on sedation, interactions, and when to stop and call the team
Patient teaching
- Tell your care team about all antidepressants, tramadol, MAOI history, and herbal supplements before starting this muscle relaxant
- This medicine is for short-term spasm (about 2–3 weeks)—call if pain lasts longer
- May cause drowsiness and dizziness—do not drive until you know how it affects you; avoid alcohol
- Report agitation, fever, fast heartbeat, stiff muscles, twitching, severe confusion, or fainting immediately
- Do not take extra tablets—even one extra dose can worsen sedation or heart effects
The Hold Rule
Do not give and contact the prescriber or pharmacist when:
- Known hypersensitivity to cyclobenzaprine
- MAO inhibitor use or MAOI within 14 days
- Contraindicated cardiac conditions (recent MI, arrhythmias, heart block, CHF, hyperthyroidism)
- Moderate–severe hepatic impairment
- Active serotonergic therapy without prescriber-approved plan (SSRI, SNRI, TCA, tramadol, bupropion, etc.)
- Suspected serotonin syndrome or cyclobenzaprine overdose (marked sedation, hyperreflexia, hyperthermia, QRS widening, seizures)
- Total IR daily dose would exceed 30 mg without prescriber documentation
- Severe sedation, syncope, or inability to arouse
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
On med-surg and urgent-care units, cyclobenzaprine is often ordered as a “muscle relaxer” without a structured interaction check. Build serotonergic screening into the same workflow as opioid and anticoagulant reconciliation.
1. Check-before-you-give protocol
- Right patient, drug, dose, formulation (IR/ER), route, and time
- MAOI-free interval ≥ 14 days documented or verified with pharmacy
- Home and inpatient serotonergic medicines reconciled—including PRN tramadol
2. High-alert and safety badge
Not a universal high-alert drug, but serotonin syndrome and cardiac overdose can be life-threateningTreat MAOI contraindication and SSRI co-therapy with the same rigor as high-alert medications: independent interaction review and clear handoff language.
3. Clinical workflow: hold and question rules
- If SSRI is started during admission, hold cyclobenzaprine until prescriber/pharmacy documents plan
- If patient took extra dose at home, clarify total 24-hour amount before next scheduled dose
- If spasm persists beyond 2–3 weeks, question continued need versus alternate diagnosis
4. Critical teach-back questions
- “What medicines must you tell us about before taking this muscle relaxant?” (Antidepressants, tramadol, MAOI history.)
- “What symptoms mean you should call right away?” (Fever, agitation, fast heartbeat, confusion, severe stiffness.)
5. Care coordination
Pharmacist: Serotonergic interaction review, IR/ER verification, hepatic dosing, overdose guidance
Prescriber / PT: Short-term spasm plan, rest and therapy goals, alternative agents if interactions prohibit cyclobenzaprine
🧠 Quick mental checklist
- Any MAOI in the last 14 days?
- Any SSRI, SNRI, TCA, tramadol, or bupropion on the profile?
- Is total IR dose ≤ 30 mg today?
- Any fever, agitation, hyperreflexia, or diaphoresis after the last dose?
- Is therapy still within the 2–3 week short-term window?
Cyclobenzaprine NCLEX practice questions
Practice NCLEX-style clinical judgment practice for cyclobenzaprine with a tabbed acute-spasm case (MAR, labs, history, nursing notes) featuring cyclobenzaprine plus home sertraline, then priority action, serotonin syndrome cue recognition, deterioration trends, documentation cloze, sedation/overdose judgment, and matrix urgency—recognize cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Cyclobenzaprine 10 mg PO TID — day 2 of admission; 0800 dose given; 1400 due
- 1400: nurse held pending assessment after patient reports “feeling strange”
- Home sertraline 50 mg daily — not listed on inpatient MAR until pharmacy reconciliation at 1300
- Acetaminophen 650 mg PO q6h PRN — one dose 0700 for spasm-related pain
- Admission ALT 22 U/L; AST 24 U/L — within normal limits
- Today BMP: sodium 140 mEq/L, potassium 4.0 mEq/L, creatinine 0.8 mg/dL
- No ammonia or ethanol level ordered
- 48-year-old admitted for acute lumbar spasm after lifting injury; no cardiac history
- Home medications per family: sertraline 50 mg daily for depression; denies MAOI use
- No alcohol reported; no known drug allergies
- Prior musculoskeletal care: ibuprofen PRN at home with partial relief
- 1300: Patient restless, diaphoretic, fine tremor; states “I feel overstimulated”
- Vitals 1300: T 38.3 °C, HR 112, BP 154/92, RR 18, SpO2 97% room air
- Neuro: alert but agitated; hyperreflexia at patellar reflexes; pupils 4 mm reactive
- Muscle spasm improved; concern is autonomic and neurologic change after cyclobenzaprine start
Answer key & rationale
Frequently asked questions
Why is serotonin syndrome the main nursing concern with cyclobenzaprine?
U.S. prescribing information warns that cyclobenzaprine is structurally related to tricyclic antidepressants and may cause serotonin syndrome when combined with serotonergic drugs such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Signs include agitation, hallucinations, hyperthermia, tachycardia, labile blood pressure, hyperreflexia, tremor, incoordination, diaphoresis, and GI symptoms. Discontinue cyclobenzaprine and serotonergic agents and initiate supportive care per protocol.
How long must a patient be off MAO inhibitors before cyclobenzaprine?
Cyclobenzaprine is contraindicated in patients taking MAO inhibitors and in patients who have used an MAOI within 14 days. Allow at least 14 days after stopping an MAOI before starting cyclobenzaprine unless pharmacy and prescriber document a different interval per product labeling and local policy.
What is the maximum daily cyclobenzaprine dose for immediate-release tablets?
For immediate-release cyclobenzaprine, usual dosing is 5 mg three times daily, which may be increased to 10 mg three times daily. The maximum recommended dose is 30 mg per day. Therapy should be limited to short-term use of two to three weeks for acute painful musculoskeletal spasm.
Is there a specific antidote for cyclobenzaprine overdose?
Prescribing information does not list a specific antidote. Overdose may cause drowsiness and tachycardia; severe cases may include cardiac arrest, seizures, and QRS widening. Management includes gastric decontamination when appropriate, ECG monitoring, supportive care, and sodium bicarbonate for dysrhythmias per label and toxicology guidance.
Can patients breastfeed while taking cyclobenzaprine?
It is not known whether cyclobenzaprine is excreted in human milk. Because the drug is closely related to tricyclic antidepressants, which may be excreted in milk, use caution when cyclobenzaprine is administered to a nursing woman. Consult LactMed and the care team to weigh maternal need against infant risk.
References
-
U.S. National Library of Medicine. CYCLOBENZAPRINE — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1aae221-4fa4-6a7e-e053-2a95a90af215
-
Drugs and Lactation Database (LactMed). Cyclobenzaprine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM517/
-
National Library of Medicine. MedlinePlus: Cyclobenzaprine.https://medlineplus.gov/druginfo/meds/a682514.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.